# Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-experimental-antibody-drug-conjugate-neck.html) · 2026-11-19 · Medicine
Page: https://themorning.science/story/experimental-antibody-drug-conjugate-shows-promising-initial-activity-in-head-an-08208a7770d61c98
Kind: research · Impact: low

## In brief

- A Phase I trial of the investigational antibody-drug conjugate micvotabart pelidotin (MICVO, PYX-201) showed promising antitumor activity in head and neck cancers.
- The trial reported a manageable safety profile.
- The results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

## Why it matters

This is early-stage evidence from a Phase I trial, so it shows initial activity and safety rather than efficacy, and science readers should watch for later-phase results before drawing conclusions about treatment benefit.

## Coverage

- [Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers](https://medicalxpress.com/news/2026-11-experimental-antibody-drug-conjugate-neck.html) — Medical Xpress - latest medical and health news stories, 2026-11-19

Tags: cancer, antibody-drug conjugate, clinical trial, head and neck cancer, oncology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
